Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,844.19
-0.17%
DAX
26,391.42
+0.26%
CAC 40
8,714.94
-0.13%
STOXX 50
6,551.22
+0.24%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Thursday 28 January 2021 9:33 am

EU and AstraZeneca hold crisis talks to resolve Covid vaccines row

By: Damian Shepherd

Add as a preferred source on Google

The EU and UK-based Covid vaccine maker AstraZeneca have vowed to resolve clashes over supply shortages after “constructive” crisis talks.

Production issues means that AstraZeneca can deliver only a fraction of the doses promised to the EU in the first quarter of the year, leading to shortages across the 27-member bloc.

The EU has remained firm, insisting the company should divert stock from the UK to honour its delivery commitments.

The AstraZeneca vaccine, developed by Oxford University, is expected to be approved by the EU on Friday.

The bloc is likely to receive 60 per cent fewer doses than promised, amounting to 50 million less jabs.

Clashes

EU Health Commissioner Stella Kyriakides had criticised the lack of clarity on the delivery schedule, questioning the logic of AstraZeneca’s “first-come first-serve” attitude.

AstraZeneca CEO Pascal Soriot told Italian newspaper La Repubblica that the contract compelled the company to make its “best effort”, rather than meeting a set deadline for vaccine delivery.

Kyriakides was quick to condemn this characterisation of the deal, deeming it “not correct or acceptable”.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Renewed unity

After bloc representatives met with AstraZeneca on Wednesday evening, the vaccine maker committed to close co-ordination with the EU to chart a path for delivery over the coming months.

Kyriakides took to Twitter to promote unity rather than division.

We regret the continued lack of clarity on the delivery schedule and request a clear plan from AstraZeneca for the fast delivery of the quantity of vaccines that we reserved for Q1. We will work with the company to find solutions and deliver vaccines rapidly for EU citizens.

— Stella Kyriakides (@SKyriakidesEU) January 27, 2021

What are the supply issues?

Soriot believes production is two months behind where AstraZeneca aimed to be due to production delays at plants in the Netherlands and Belgium.

The EU signed a deal in August for 300 million doses, with an option for 100 million more.

Only 50 million have been received and Italy is among the countries threatening to sue over the delays.

What about other vaccines?

The EU has also ordered 2.3 billion doses from four other companies but only the Pfizer and Moderna vaccines have been approved.

Pfizer has failed to supply the 12.5 million vaccines it promised by the end of 2020, meaning Madrid has halted most vaccinations for a fortnight as supplies become threatened.

The EU has vowed to restrict the exports of vaccines made within the bloc to deal with the shortfall.

Read more

Astrazeneca share price tumbles on $400bn megamerger talks

Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • AstraZeneca
  • Brexit
  • Company
  • Coronavirus
  • Vaccine

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • Oil price falls but Trump and Iran clash on negotiations claim

    Markets
    Donald Trump smiling in a blue suit and tie with an American flag pin, US flag in background
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Oil prices return to crisis levels

    Markets
    Close-up of a petrol pump nozzle dispensing fuel at a gas station, highlighting rising fuel costs and economic impact.
  • As it happened: Stocks fall as oil creeps up; Trump to ‘finish job’ in Iran

    Markets
    Donald Trump speaking at the PAAP office conference, addressing key political issues and strategies in a formal setting.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook